UNSPSC 51183902: Ragaglitazar

This classification denotes an anti-diabetic agent with the molecular formula C25H25NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) Q5ELR5A7Y5, chemically known as benzenepropanoic acid, alpha-ethoxy-4-(2-(10h-phenoxazin-10-yl)ethoxy)-, (alphas)- but more generally known as ragaglitazar, which bears US NIH Compound Identifier 128814. The term RAGAGLITAZAR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 16., No. 1.2002, List 47).

Most nations, for tariff and trade purposes, schedule ragaglitazar under HS 29349990 and SITC 51579. As of Q4 2014, RAGAGLITAZAR remains US FDA's Preferred Term for this commodity. Ragaglitazar bears US NLM identifiers UMLS ID C1175029 and NCI Concept Code C75192. SMILES: CCOC(CC1=CC=C(C=C1)OCCN2C3=CC=CC=C3OC4=CC=CC=C42)C(=O)O.

UNSPSC 51183902 Ragaglitazar, a Commodity code, encompasses prescription pharmaceutical products that state and local health systems and cooperative purchasing consortia source through multistate agreements, typically acquiring specific branded or generic drugs identified by National Drug Code for distribution across participating agency facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) recently solicited vendors to supply generic multi-source pharmaceuticals and over-the-counter products across participating state and local facilities including Oregon, demonstrating how jurisdictions use cooperative vehicles to aggregate demand and negotiate manufacturer pricing. The scope includes comprehensive product data submission—NDC codes, SKUs, UPCs, dosage forms, packaging configurations, and manufacturing locations—combined with cGMP and Drug Supply Chain Security Act compliance certification and contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) equipped with chargeback systems. Evaluation emphasizes price competitiveness at seventy-five percent weight, with secondary factors including fixed pricing structure, administrative fee compliance, and electronic data interchange capability. Vendors must carry workers' compensation, $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage.

The Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP with a March 26, 2026 response deadline (questions due February 18, 2026) for multi-award agreements effective July 1, 2026, with a two-year initial contract term and optional extensions at MMCAP's discretion. Awarded vendors will be available to authorized wholesalers by May 15, 2026. Submissions require ePro system access via Google Chrome and detailed product information in Excel-to-CSV format, with pricing options including flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures. All products must meet FDA requirements, possess expiration dates of at least one year from manufacture, and maintain a minimum six-month shelf life. MMCAP reserves sole-, dual-, or multi-award decisions based on therapeutic considerations, product availability, patient safety, and member-specific needs; no specific award values or budget ranges were disclosed. Performance penalties range from $200 to $1,500 per violation for issues such as late reporting, missed onboarding timelines, or improper class-of-trade denials.